Revital Healthcare EPZ Ltd. Achieves WHO Prequalification for Early-Activation Auto-Disable Syringe: A Milestone for African Manufacturing and Immunization Programming
Revital Healthcare EPZ Ltd. stands as the exclusive African manufacturer granted WHO PQ status for their early activation auto-disable (AD) syringe.
Official Press Release
Mombasa, Kenya – [26th September 2023] – Revital Healthcare EPZ Ltd., a leader in African medical device manufacturing, announces a historic milestone in African manufacturing excellence. The company is the first to be granted Pre-Qualification (PQ) status by the World Health Organization (WHO) on July 11, 2023 for their early activation auto-disable (AD) syringe in Africa. This marks Revital’s more than ten-year commitment to injection safety in immunization programming across Africa.
The early-activation feature is the gold standard for safety in Immunization programs as preferred by UNICEF, and renders the syringe disabled at the start of administering and injection. Historically, the introduction of these devices have resulted in substantial reductions in rates of blood-borne infections such as HIV in immunization programs across Africa.
There are currently eight manufacturers who have WHO PQ status for this product, however Revital’s is the first and only to be produced in Africa. This is expected to decrease average syringe transport times by up to 80-90% for Africa, critical for rapid outbreak response and timely immunization campaigns.
Roneek Vora, Director of Marketing and Sales for Revital Healthcare EPZ Ltd., comments, “Revital’s historic WHO pre-qualification for the early-activation AD syringe exemplifies the transformative power of African innovation and manufacturing excellence. Our commitment to the well-being of our fellow people, especially children receiving life-saving immunization, is our motivation to continue to progress.”
Revital will be able to produce upwards of 300 million AD syringes per year.
This work was made possible through a grant from the Bill & Melinda Gates Foundation. In addition to supporting the development of this product to increase supply security for Africa, this helped create more than 200 new local jobs in Kilifi County, 80% of which are staffed by women in support of a joint commitment to gender equality.
“As the first African manufacturer to be approved by WHO to produce early activation auto-disable syringes, Revital is paving the way to expand local production of syringes,” said Violaine Mitchell, Director of Immunization at the Bill & Melinda Gates Foundation.
“We are proud to support Revital’s efforts to sustainably expand the supply of these syringes in Africa and ensure vaccines are delivered safely and quickly across the continent.”
The WHO PQ listing for the 0.5ml early-activation AD syringe can be accessed through the WHO Vaccine Quality Catalogue.
First African Manufacturer
Revital is the sole African producer to hold WHO PQ status for their early activation auto-disable (AD) syringe.
Impact and Innovation
Revital’s achievement reflects African innovation and commitment to immunization safety and supply security
Enhanced Syringe Safety
The early-activation feature in Revital’s syringe sets a gold standard, reducing blood-borne infections in immunization programs.
Impact On Global Healthcare
Impossible to alter or tamper
Reduces blood-borne infection risk
Reduced Medical Waste
Reduces medical waste and associated disposal costs
Reduces the transmission of diseases like HIV and hepatitis
Delivers precise and consistent dosages
Reliable delivery of vaccines
One-time use nature reduces the risk of contamination
Stringent quality control measures
Easy to handle and administer medications
Have Any Questions?
Manufacturing Capacity Annually
New Jobs Generated
Manufacturing Capacity Annually
New jobs generated
Gain a better understanding of Revital’s early activation auto-disable (AD) syringes with these frequently asked questions.
What is Revital's early activation auto-disable (AD) syringe?
Revital’s AD Early Activation Syringe is designed to disable at the start of injection to ensure enhanced safety by stopping the chance of re-use.
Why is Revital's AD syringes important in healthcare?
Revital’s AD syringes play a crucial role in reducing the risk of blood-borne infections, enhancing injection safety, and preventing medication errors.
How will Revital's AD syringes improve immunization programs?
Revital’s AD syringes ensure precise dosing, prevent needle reuse, and reduce contamination, leading to safer and more effective immunization campaigns.
Is Revital's AD syringe compatible with different medications and vaccines?
Yes, Revital’s AD syringes are designed to be compatible with a wide range of medications and vaccines, making them versatile for various healthcare applications.
What are the environmental benefits of Revital's AD syringes?
Revitals AD Syringe requires less plastic during the manufacturing process and hence generating less medical waste, which contributes to reduced disposal costs and a smaller environmental footprint.
State Of The Art
Head Of International BD
Our Patent Holders
Buzz on WHO Prequalification
“Our successful WHO Prequalification for the early activation auto-disable syringe marks a significant milestone in our commitment to healthcare excellence. This recognition validates our syringe’s rigorous adherence to stringent international standards, ensuring its efficacy, safety, and reliability in diverse healthcare settings globally.”
Chairman and Founder, Revital Healthcare EPZ Ltd
“Revital’s historic WHO pre-qualification for the early-activation AD syringe exemplifies the transformative power of African innovation and manufacturing excellence. Our commitment to the well-being of our fellow people, especially children receiving life-saving immunization, is our motivation to continue to progress.”
Director of Marketing and Sales, Revital Healthcare EPZ Ltd
“I am thrilled by our achievement of WHO Prequalification for the early activation auto-disable syringe. This accomplishment reflects our dedication to manufacturing precision and the highest quality standards, further solidifying our position as a global healthcare leader, and setting new benchmarks for innovation in medical device manufacturing.
Director of Operations, Revital Healthcare EPZ Ltd
Latest News & Resources
Press ReleaseRevital Healthcare EPZ Ltd. Achieves WHO Prequalification for Early-Activation Auto-Disable Syringe: A Milestone for African Manufacturing and Immunization ProgrammingRevital Healthcare EPZ Ltd. stands as the exclusive African manufacturer granted WHO PQ...
Blog News &UpdatesRevital Healthcare banks blanket contractfrom a key global organisationRevital Healthcare has recently secured a notable contract with a global organization to supply India with 50 million units of 2ML vaccine syringes amidst concerns over a...
Blog News &UpdatesRevital becomes sole company in African to manufacture Covid-19 vaccine syringesRevital Healthcare (EPZ) Limited has gained international recognition for its efforts in the fight against the Covid-19 pandemic. The company has earned the...
Blog News &UpdatesUkraine using Revital-made bCPAP device to save premature babiesPremature babies in Ukraine with breathing difficulties are being saved by a device made in Kenya. The bCPAP device, produced by Africa's largest medical manufacturer - Revital...
Blog News &UpdatesRevital Exported 70 Million Covid-19 Vaccine SyringesRevital Healthcare has been globally acknowledged for its role in exporting more than 70 million Covid-19 vaccine syringes during the pandemic. The then President of Kenya, Uhuru Kenyatta,...
Blog News &UpdatesRevital unveils bCPAP - first-ever non-electric respiratory device to save babiesRevital Healthcare has achieved a remarkable feat by becoming the world's first manufacturer of a respiratory device specifically designed to support neonates and...